IB Net Payout Yields Model

Johnson & Johnson: Expect Underwhelming Results To Continue

JNJ dipped after underwhelming guidance for 2018.
The stock has lagged the market rally due to a stretched valuation and limited growth.
The lack of additional capital returns is a negative signal for the stock.
Despite the gains of the last year, Johnson & Johnson (JNJ) hasn't actually outperformed the market. In fact, the stock has now vastly underperformed the market since the start of November and reinforces the valuation questions that exist with this healthcare stock and ongoing negative signals from the company.
 Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please read the disclaimer page for more details. 



Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders